Similar Papers

Paper Title
Journal
Date
Author
Cisplatin–gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients
Nebu Koshy ... Gary V Burton
The Breast | VOL. 19
Nebu Koshy, et. al.Nebu Koshy ... Gary V Burton
15 Mar 2010
PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland
Anna Kluska ... Katarzyna Czarny
BMC Medical Genomics | VOL. 10
Anna Kluska, et. al.Anna Kluska ... Katarzyna Czarny
09 Mar 2017
Abstract P5-15-04: Oncotype DX cost effectivity to a Brazilian public hospital
C Cabello ... S Teixeira
Cancer Research | VOL. 79
C Cabello, et. al.C Cabello ... S Teixeira
15 Feb 2019
P85-2 Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital
C.C Arenos ... T Uy
Annals of Oncology | VOL. 35
C.C Arenos, et. al.C.C Arenos ... T Uy
01 Oct 2024
View more papers

More From: ecancermedicalscience

Paper Title
Journal
Date
Author
Determinants of cancer care pathways at Wajir County, Kenya: patient perspectives
Fatuma Affey ... Omar Abdihamid
ecancermedicalscience | VOL. -
Fatuma Affey, et. al.Fatuma Affey ... Omar Abdihamid
07 Feb 2025
Trends in gastrointestinal cancer burden in Zimbabwe: 10-year retrospective study 2009–2018
Tinashe Adrian Mazhindu ... Kevin Grimes
ecancermedicalscience | VOL. 19
Tinashe Adrian Mazhindu, et. al.Tinashe Adrian Mazhindu ... Kevin Grimes
06 Feb 2025
Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine Tertiary Government Hospital
Carl Arenos ... Michael San Juan
ecancermedicalscience | VOL. -
Carl Arenos, et. al.Carl Arenos ... Michael San Juan
06 Feb 2025
Expression of cyclooxygenase-2 (COX-2) in epithelial ovarian cancers in an Indigenous African population of Kano, Nigeria
Jimoh Ajanaku Abdulrazaq ... Richard Kelechi Samuel
ecancermedicalscience | VOL. 19
Jimoh Ajanaku Abdulrazaq, et. al.Jimoh Ajanaku Abdulrazaq ... Richard Kelechi Samuel
05 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.